Table 2.
Comparison of antimicrobial use among the eighta MDRAB cases before and after the occurrence of MDRAB
| Before | After | P value | |
|---|---|---|---|
| Time-at-risk, patient-daysb | 130 | 98 | |
| All antibiotics, DOT (DOT/1000 patient-days) | 1923 (1685–2161) | 2286 (1986–2585) | 0.113 |
| Carbapenem | 708 (563–852) | 469 (334–605) | 0.003 |
| Non-carbapenem Beta-lactam | 246 (161–331) | 612 (457–767) | < 0.001 |
| Glycopeptide | 846 (688–1004) | 939 (747–1131) | 0.424 |
| Miscellaneous | 123 (63–183) | 265 (163–367) | 0.016 |
| Antifungal agent | 392 (285–500) | 765 (592–939) | < 0.001 |
aOne of the nine patients was excluded from the analysis. For this patient, only one MDRAB isolate was discovered from a removed central venous catheter (CVC) and there was no further MDRAB isolation from CVC available during study period. Thus, clearance of MDRAB was not defined and the analysis did not include the patient
bTime-at-risk before MDRAB occurrence was the time from admission to MDRAB isolation. Time-at-risk after MDRAB occurrence was the time from MDRAB isolation to MDRAB clearance
Data are expressed as days of therapy (DOTs) and accumulated DOTs per 1000 patient-days
DOT days of therapy, MDRAB multidrug-resistant Acinetobacter baumannii